Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA III Could Move Through Congress In 2001, Rep. Burr Suggests

This article was originally published in The Tan Sheet

Executive Summary

FDA's post-approval surveillance system should be discussed as part of the reauthorization process for the Prescription Drug User Fee Act, Rep. Richard Burr (R-N.C.) said during a May 3 House Energy & Commerce Committee/Health Subcommittee hearing on implementation of the FDA Modernization Act.
Advertisement

Related Content

PDUFA III Authorizes FDA To Alert Doctors Of Failed Phase IV Commitments
PDUFA III Authorizes FDA To Alert Doctors Of Failed Phase IV Commitments
PDUFA III Authorizes FDA To Alert Doctors Of Failed Phase IV Commitments
FDA PDUFA II Update Emphasizes Need To Reauthorize Act Before Sunset
FDA PDUFA II Update Emphasizes Need To Reauthorize Act Before Sunset
FDA PDUFA II Update Emphasizes Need To Reauthorize Act Before Sunset
Pediatric Labeling Negotiations Limited To Six Months In Reauthorization Bill
Pediatric Labeling Negotiations Limited To Six Months In Reauthorization Bill
Pediatric Study Incentive Could Be Tax Credit, Not Exclusivity - Rep. Pallone
Pediatric Study Incentive Could Be Tax Credit, Not Exclusivity - Rep. Pallone

Topics

Advertisement
UsernamePublicRestriction

Register

PS092520

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel